Shares in AstraZeneca (LON:AZN) slumped on reports the UK pharmaceutical giant has held merger talks with US-based rival Bristol Myers Squibb (NYSE:BMY). Should it come to pass, a combination would create one of the globe’s biggest pharmaceutical groups worth almost $400 billion. So why is the market cool on the idea? Well, investors and analysts … Continue reading AstraZeneca tumbles as Bristol Myers Squibb talks baffle investors